Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT

THE 2019 THIRD EXTRAORDINARY GENERAL MEETING

HELD ON MONDAY, 30 DECEMBER 2019

The board (the ''Board'') of directors (the ''Directors'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') is pleased to announce the poll results of the 2019 third extraordinary general meeting (the ''EGM'') held at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the People's Republic of China on Monday, 30 December 2019 at 1:30 p.m..

References are made to the notice of the EGM and the circular of the Company (the ''Circular''), both dated 12 November 2019. Unless the context otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, (i) the total number of the issued shares of the Company (the ''Shares'') was 2,562,898,545 Shares, comprising 2,010,958,045 A Shares and 551,940,500 H Shares; and (ii) holders of 2,562,898,545 Shares (or authorized proxies) were entitled to attend and vote on the resolutions proposed at the EGM. There were no Shares entitling the shareholders of the Company (the ''Shareholders'') to attend and vote only against the resolutions at the EGM.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting at the EGM.

- 1 -

ATTENDANCE AT THE EGM

Set out below are the details of the Shareholders and authorized proxies present at the EGM:

Number of Shareholders and authorized proxies

37

Including:

Number of A Shareholders

36

Number of H Shareholders

1

Total number of Shares carrying voting rights (shares)

1,171,397,646

Including:

Total number of Shares carrying voting rights held by

974,360,114

A Shareholders

Total number of Shares carrying voting rights held by

197,037,532

H Shareholders

Percentage of the total number of Shares (%)

45.7060%

Including:

Number of A Shares as a percentage of the number of Shares

38.0179%

Number of H Shares as a percentage of the number of Shares

7.6881%

The EGM were convened in compliance with the requirements of the Company Law of the People's Republic of China and the articles of association of the Company (the ''Articles of Association''), and was chaired by Mr. Chen Qiyu, the chairman of the Company.

In compliance with the requirements of the Hong Kong Listing Rules and Article 115 of the Articles of Association, BDO Limited, Grandall Law Firm (Shanghai), the Company's PRC legal advisers, Shareholder's representatives and members of the supervisory committee of the Company acted as the scrutineers for the vote-counting at the EGM.

- 2 -

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE EGM

The resolutions at the EGM were voted by poll. The poll results in respect of the resolutions proposed at the EGM are as follows:

Ordinary Resolution

Number of valid votes (%)

For

Against

Abstain

1.

To consider and approve the resolution in

1,161,974,395

4,802

9,418,449

relation to the compliance of the Overseas

(99.1956%)

(0.0004%)

(0.8040%)

Listing of Gland Pharma with the Circular on

Issues in Relation to Regulating Overseas

Listing of Subsidiaries of Domestic Listed

Companies.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2. To consider and approve the resolution in relation to the Overseas Listing of Gland Pharma item by item:

2.01 Issuing entity;

1,161,974,395

4,802

9,418,449

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.02 Place of listing;

1,161,974,395

4,802

9,418,449

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.03 Type of securities to be issued;

1,161,974,395

4,802

9,418,449

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.04 Nominal value;

1,161,974,395

4,802

9,418,449

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.05 Target subscribers;

1,161,974,395

4,802

9,418,449

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

- 3 -

Ordinary Resolution

Number of valid votes (%)

For

Against

Abstain

2.06 Listing date;

1,161,974,395

4,802

9,418,449

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.07 Method of issuance;

1,161,974,395

4,802

9,418,449

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.08 Size of issuance;

1,161,974,395

4,802

9,418,449

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.09 Pricing method;

1,161,974,395

4,802

9,418,449

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.10 Underwriting;

1,161,974,895

4,802

9,417,949

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.11 Use of proceeds; and

1,161,974,395

4,802

9,418,449

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.12 The public offering arrangement of the shares

1,161,974,395

4,802

9,418,449

of Gland Pharma held by the Company.

(99.1956%)

(0.0004%)

(0.8040%)

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

3.

To consider and approve the resolution in

1,161,974,295

4,802

9,418,549

relation to the undertaking of maintaining

(99.1955%)

(0.0004%)

(0.8041%)

independent listing status.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

- 4 -

Ordinary Resolution

Number of valid votes (%)

For

Against

Abstain

4.

To consider and approve the resolution in

1,161,974,295

4,802

9,418,549

relation to the description of the sustainable

(99.1955%)

(0.0004%)

(0.8041%)

profitability and prospects.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

5.

To consider and approve the resolution in

1,161,974,295

4,802

9,418,549

relation to the authorisation to the Board and

(99.1955%)

(0.0004%)

(0.8041%)

its authorised persons to deal with full

discretion with the Overseas Listing of Gland

Pharma and the related matters.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

CERTIFICATION

As certified by and stated in the legal opinion issued by Grandall Law Firm (Shanghai), the Company's PRC legal advisers, the convening and holding of the EGM are in compliance with requirements of laws, administrative regulations, the Rules of General Meetings of Listed Companies and the Articles of Association, the qualifications of the attendees of the EGM and the convener are legally valid, and the voting procedures and voting results of the EGM are legally valid.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

30 December 2019

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang, Mr. Wang Can, Ms. Mu Haining and Mr. Liang Jianfeng; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

  • for identification purposes only

- 5 -

Attachments

  • Original document
  • Permalink

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 30 December 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 December 2019 10:45:06 UTC